Modulo Bio
@modulobio.bsky.social
Reprogramming the brain’s immune system to cure neurodegenerative disorders.
Immense gratitude to the @alsassociation.bsky.social team making this possible.
Press Release: t.co/BKepERocLZ
Press Release: t.co/BKepERocLZ
https://www.einpresswire.com/article/783811396/modulo-bio-awarded-500-000-grant-from-the-als-association-to-advance-novel-therapeutic
t.co
February 8, 2025 at 12:33 AM
Immense gratitude to the @alsassociation.bsky.social team making this possible.
Press Release: t.co/BKepERocLZ
Press Release: t.co/BKepERocLZ
This @alsassociation.bsky.social grant will support critical preclinical studies needed for our IND filing and help validate our identified biomarkers—to identify patients likely to respond to treatment.
February 8, 2025 at 12:33 AM
This @alsassociation.bsky.social grant will support critical preclinical studies needed for our IND filing and help validate our identified biomarkers—to identify patients likely to respond to treatment.
What makes this particularly promising is that our therapeutic approach has shown potential to:
• Reduce key ALS disease markers
• Enhance neuronal survival
• Work across multiple forms of ALS, including both genetic and sporadic cases, particularly C9orf72
• Reduce key ALS disease markers
• Enhance neuronal survival
• Work across multiple forms of ALS, including both genetic and sporadic cases, particularly C9orf72
February 8, 2025 at 12:33 AM
What makes this particularly promising is that our therapeutic approach has shown potential to:
• Reduce key ALS disease markers
• Enhance neuronal survival
• Work across multiple forms of ALS, including both genetic and sporadic cases, particularly C9orf72
• Reduce key ALS disease markers
• Enhance neuronal survival
• Work across multiple forms of ALS, including both genetic and sporadic cases, particularly C9orf72
Our focus? A novel brain-penetrant CSF1R inhibitor that reprograms microglia—the brain's immune cells—from harmful to protective states.
February 8, 2025 at 12:33 AM
Our focus? A novel brain-penetrant CSF1R inhibitor that reprograms microglia—the brain's immune cells—from harmful to protective states.